Quanterix Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Quanterix stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QTRX, but not buy additional shares or sell existing shares.
View analyst ratings for Quanterix or view top-rated stocks.

Wall Street analysts have given Quanterix a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Quanterix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Quanterix is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Quanterix.

Quanterix Co. (NASDAQ:QTRX) posted its quarterly earnings results on Thursday, August, 5th. The company reported ($0.33) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.01. The business had revenue of $25.37 million for the quarter, compared to analyst estimates of $23.59 million. Quanterix had a negative net margin of 26.90% and a negative trailing twelve-month return on equity of 8.76%.
View Quanterix's earnings history.

Quanterix's stock was trading at $18.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QTRX shares have increased by 171.6% and is now trading at $50.27.
View which stocks have been most impacted by COVID-19.

3 brokerages have issued 12-month target prices for Quanterix's shares. Their forecasts range from $53.00 to $75.00. On average, they expect Quanterix's stock price to reach $66.00 in the next twelve months. This suggests a possible upside of 31.3% from the stock's current price.
View analysts' price targets for Quanterix or view top-rated stocks among Wall Street analysts.

15 employees have rated Quanterix CEO Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among Quanterix's employees.

Some companies that are related to Quanterix include Coherent (COHR), Pacific Biosciences of California (PACB), Cytek BioSciences (CTKB), Olink Holding AB (publ) (OLK), HORIBA (HRIBF), Berkeley Lights (BLI), Bionano Genomics (BNGO), Singular Genomics Systems (OMIC), Rapid Micro Biosystems (RPID), Akoya Biosciences (AKYA), Fluidigm (FLDM), Accelerate Diagnostics (AXDX), Codex DNA (DNAY), EyePoint Pharmaceuticals (EYPT) and Harvard Bioscience (HBIO).
View all of QTRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Novavax (NVAX), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), The Walt Disney (DIS), Illumina (ILMN), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and Intellia Therapeutics (NTLA).

(QTRX) raised $50 million in an initial public offering on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Quanterix's stock is owned by many different institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (7.73%), BlackRock Inc. (6.58%), Vanguard Group Inc. (4.39%), Price T Rowe Associates Inc. MD (3.94%), Marshall Wace LLP (3.87%) and Frontier Capital Management Co. LLC (2.65%). Company insiders that own Quanterix stock include Amol Chaubal, David C Duffy, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, John J Fry, Marijn E Dekkers, Mark T Roskey and Martin D Madaus.
View institutional ownership trends for Quanterix.

QTRX stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Lord Abbett & CO. LLC, Morgan Stanley, Morgan Stanley, Monashee Investment Management LLC, Bellevue Group AG, Redmile Group LLC, and Victory Capital Management Inc.. Company insiders that have sold Quanterix company stock in the last year include Amol Chaubal, David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Marijn E Dekkers, Mark T Roskey, and Martin D Madaus.
View insider buying and selling activity for Quanterix or view top insider-selling stocks.

QTRX stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Millennium Management LLC, BlackRock Inc., Marshall Wace LLP, Clearbridge Investments LLC, Skandinaviska Enskilda Banken AB publ, Frontier Capital Management Co. LLC, and Monarch Partners Asset Management LLC.
View insider buying and selling activity for Quanterix or or view top insider-buying stocks.

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QTRX stock can currently be purchased for approximately $50.27.

Quanterix has a market capitalization of $1.84 billion and generates $86.38 million in revenue each year. The company earns $-31,530,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis.

Quanterix employs 314 workers across the globe.

The official website for Quanterix is www.quanterix.com.

Quanterix is headquartered at 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821.

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at (617) 301-9400 or via email at [email protected]